Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
study the pharmacokinetics of mini-pooled intravenous immunoglobulin( MP-IVIG)
Study the safety and efficacy of a newly developed preparation of MP-IVIG in children with primary immunodeficiency (PID) :
Compare the efficacy of MP-IVIG to standard IVIG in children with primary immunodeficiency (PID).
Primary immunodeficiency diseases (PID) are a heterogeneous group of inherited disorders of the immune system, predisposing individuals to recurrent infections, allergy, autoimmunity, and malignancies. Clinical descriptions have already been made for more than 200 PIDs, for which over 150 forms of PID have been molecularly characterized .
A population prevalence of diagnosed PID in the United States at approximately 1 in 1,200 persons.
A part from local registration in some centres there is no national registry of PID in Egypt, and hence, the prevalence of these disorders in the investigator's population is still unknown .
An increasing number of PID are recognized, and effective treatments are possible. Early use of prophylactic antibiotics and replacement immunoglobulin can prevent significant end organ damage and improve long quality of life in these patients .
Immunoglobulin G (IgG) is an essential plasma derived medicine that is lacking in developing countries .IgG shortages leave immune deficient patients without treatment, exposing them to devastating recurrent infections from local pathogens. A simple and practical method for producing IgG from normal plasma collected in developing countries is needed to provide better, faster access to IgG for patients .
Magdy EL-Ekiaby, et al 2010 introduce the concept of small-scale ("minipool") plasma processing methods implementable with minimum infrastructural requirements. They developed viral inactivation and protein purification technologies in single-use equipment to prepare virally safe solvent/detergent-filtered (S/D-F) plasma Producing a 90%pure immunoglobulin fraction in disposable single-use devices for transfusion as well as minipool S/D-F cryoprecipitate to treat bleeding disorders.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| minipooled- Intravenous immunoglobulin(MP-IVIG) | Experimental | • MP-IVIG equivalent to 1 g/ kg of standard IVIG over a 6-hour to 8-hour period monthly alternated by standard IVIG for a period of 12 months follow up and the newly diagnosed cases admitted to AUH in the follow up period will be included. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| minipooled- Intravenous immunoglobulin(MP-IVIG) | Other | The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters. |
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy of MP-IVIG assessed by the incidence of acute Serious Bacterial infections(SBIs) | The rate of Acute SBIs for each participant per 1 year will be assessed by questionnaire (Serious Bacterial Infections) include sign and symptoms of acute serious bacterial infections, i.e. bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, osteomyelitis/ septic arthritis, visceral abscess. | 1 year |
| Safty of MP-IVIG assessed by percentage of adverse Events | Overall percentage of adverse events as hemolysis and anaphylaxis headache and other complains that occur during 72 hours of following an infusion of MP-IVIG will be assessed by1) vital sign(pulse,blood pressure,Respiratory rate and temprature 2)Hemolysis by hemoglobin level,LDH,billirubin level.2)lbetwen infusions by home diaries. | 72 hour after adminstration of MP-IVIG and betwen infusions period |
| Study the pharmacokinetics- MP-IVIG trough levels | MP-IVIG trough level concentration values of serum total IgG pre the MP-IVIG infusion (if applicable). | predose sample |
| Study the pharmacokinetics MP-IVIG plasma concentration -time curve | Blood samples for analysis of pharmacokinetics MP-IVIG plasma concentration -time curve were obtained and analysed | (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose |
| Study the pharmacokinetics MP-IVIG half-life | Blood samples for analysis of pharmacokinetics MP-IVIG haf-life were obtained and analysed | (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose |
| Study the pharmacokinetics MP-IVIG area under the curve |
| Measure | Description | Time Frame |
|---|---|---|
| Compare efficacy of MP-IVIG vs standard IVIG by compare incidence of SBIs of both | • Compare the efficacy of MP-IVIG to standard IVIG in children with Primary immunodeficiency disease (PID). | 1 year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Maha A Mohammed, professor | Assiut University | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Faculty of Medicine | Asyut | Egypt |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 19778318 | Background | El-Ekiaby M, Sayed MA, Caron C, Burnouf S, El-Sharkawy N, Goubran H, Radosevich M, Goudemand J, Blum D, de Melo L, Soulie V, Adam J, Burnouf T. Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. Transfus Med. 2010 Feb;20(1):48-61. doi: 10.1111/j.1365-3148.2009.00963.x. Epub 2009 Sep 23. | |
| 17577648 |
| Label | URL |
|---|---|
| Gathmann B, Grimbacher B, Beauté J, Dudoit Y, Mahlaoui N, Fischer A(2009):. ESID Registry Working Party. The European internet based patient and research database for primary immunodeficiency: results 2006-2008. Clin Exp Immuno. | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D000081207 | Primary Immunodeficiency Diseases |
| ID | Term |
|---|---|
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
Not provided
Not provided
Single Group Assignment
Not provided
Not provided
Not provided
Not provided
|
Blood samples for analysis of pharmacokinetics MP-IVIG haf-life were obtained and analysed |
| (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose |
| Study the pharmacokinetics MP-IVIG Cmax | Blood samples for analysis of pharmacokinetics MP-IVIG Cmax were obtained and analysed | (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose |
| Study the pharmacokinetics of MP-IVIG-Tmax. | Blood samples for analysis of pharmacokinetics MP-IVIG Tmax were obtained and analysed | (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose |
| Study the pharmacokinetics of MP-IVIG elimination rate constant(s). | Blood samples for analysis of pharmacokinetics MP-IVIG elimination rate constant(s) were obtained and analysed | (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose |
| Background |
| Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007 Sep;27(5):497-502. doi: 10.1007/s10875-007-9103-1. Epub 2007 Jun 19. |
| 19002574 | Background | Reda SM, Afifi HM, Amine MM. Primary immunodeficiency diseases in Egyptian children: a single-center study. J Clin Immunol. 2009 May;29(3):343-51. doi: 10.1007/s10875-008-9260-x. Epub 2008 Nov 11. |
| 18241226 | Background | Piguet D, Tosi C, Luthi JM, Andresen I, Juge O; Study investigators. Redimune NF Liquid, a ready-to-use, high-concentration intravenous immunoglobulin therapy preparation, is safe and typically well tolerated in the routine clinical management of a broad range of conditions. Clin Exp Immunol. 2008 Apr;152(1):45-9. doi: 10.1111/j.1365-2249.2008.03597.x. Epub 2008 Jan 28. |